Sun Pharmaceutical Industries Ltd said it clocked a 26.2 per cent growth in net profit, at ₹2,714 crore, for the fourth quarter ended March 31, 2026.
The drugmaker’s sales for the fourth quarter stood at ₹14,559 crore, up 13.6 per cent. Its global innovative medicines (formerly specialty medicines) sales was $354 million. This was 20.1 per cent and accounted for 22.2 per cent of sales. The company’s EBITDA was ₹3,954 crore, up 6.4 per cent. EBITDA margin was 27.1 per cent. Its research and development investment stood at ₹975 crore, at 6.7 per cent of sales.
Kirti Ganorkar, Sun Managing Director, said, “Our full-year performance reflects several significant achievements. Sun’s 0.3 percentage points gain in the India market is our highest gain since the Ranbaxy acquisition. Our US Innovative Medicines business has surpassed USD1 billion in revenues, while Ex-US Innovative Medicines continues to demonstrate strong growth momentum. The recently announced Organon acquisition is expected to further accelerate Sun’s transformation into a leading global pharmaceutical company.”
For the year ended March 31, 2026 (FY26), the company’s net profit was up 5 per cent, at Rs 11,479 crore. Its sales stood at Rs 58,220 crore, up 11.9 per cent. Its global innovative medicines sales clocked $1,420 million, 16.4 per cent and accounting for 20.7 per cent of sales, both ex-milestone, the company said. Its EBITDA was ₹17,731 crore, up 16.1 per cent. The EBITDA margin was 30.3 per cent.
The company’s board of directors proposed a final dividend of ₹5 per share for the year FY26. This is in addition to the interim dividend of ₹11 per share paid in FY26, taking the total dividend for FY26 to ₹16 per share, same as FY25, the company said.
Published on May 22, 2026